SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: margie who wrote (655)4/29/1997 3:22:00 PM
From: tommysdad   of 6136
 
Now, I'm pretty new to this thread, but am very familiar with Agouron. My expertise is not finance, but science, so I can't comment on "LMoss"'s numbers. But when he talks about chemistry, he doesn't know what he is talking about.

Viracept and Crixivan are, in fact, VERY SIMILAR structurally. That is a natural result of having been designed to fit into the same enzyme at the same place using the same techniques. And Viracept actually has five (5, count 'em) "chiral centers".

What does this mean to an Agouron investor? Nothing by itself. But if he SO wrong on the science end, how can I trust his business conclusions?

BTW, I think Agouron is a great company, but everyone should know the facts.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News